BreStem is working to fight pulmonary fibrosis through stem cell therapy for lung regeneration. Our rapid and robust method generates therapeutically-relevant amounts of lung stem cells that outperform current treatment options.
BreStem Therapeutics is a clinical stage biopharmaceutical company, committed to developing potentially transformative cell and cell-free therapies for pulmonary fibrosis and potentially other respiratory related diseases. Utilizing our proprietary cell culture and manufacturing technology, BreStem has a pipeline of products in development for the treatment of pulmonary fibrosis with possible expansion into other respiratory related diseases.
Led by a world-class leadership team with more than 40+ years experience in respiratory research and bioengineering, we are developing a diverse pipeline of patient-specific cells therapy as well as "off-the-shelf" ready stem cell product with the goal of delivering readily available cell-free therapies faster, more reliably and at greater scale to more patients around the world.